Clinical Trial: Nivolumab and Ipilimumab in Treating Patients With Rare Tumors

Study Status: Recruiting
Recruit Status: Recruiting
Study Type: Interventional




Official Title: DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors

Brief Summary: This clinical trial studies nivolumab and ipilimumab in treating patients with rare tumors. Monoclonal antibodies, such as nivolumab and ipilimumab, may interfere with the ability of tumor cells to grow and spread.